SG/PUT/VERTEX PHARMACEUTICALS/350/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 15:41:26 2024-06-25 EDT | ||
| 0.16 EUR | +14.29% |
|
| Current month | -46.67% | ||
| 1 month | -54.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 0.16 | +14.29% |
| 24-06-24 | 0.14 | -17.65% |
| 24-06-21 | 0.17 | +21.43% |
| 24-06-20 | 0.14 | -12.50% |
| 24-06-19 | 0.16 | -11.11% |
Delayed Quote Deutsche Boerse AG
Last update June 25, 2024 at 03:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SV6Q1J |
| ISIN | DE000SV6Q1J7 |
| Date issued | 2023-05-24 |
| Strike | 350 $ |
| Maturity | 2024-09-20 (87 Days) |
| Parity | 10 : 1 |
| Emission price | 4.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.68 € |
|---|---|
| Lowest since issue | 0.085 € |
| Spread | 0.01 € |
| Spread % | 6.25% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Warrants
- Warrant
